The role of positive feedback loops involving anti-dsDNA and anti-anti-dsDNA antibodies in autoimmune glomerulonephritis

被引:0
|
作者
Arazi, A. [1 ,2 ]
Neumann, A. U. [1 ,2 ]
机构
[1] Bar Ilan Univ, Fac Life Sci, Ramat Gan, Israel
[2] Humboldt Univ, Inst Theoret Biol, D-10099 Berlin, Germany
关键词
Autoimmune glomerulonephritis; Systemic lupus erythematosus; Autoimmune inflammation; Anti-idiotypic antibodies; TLR9; SYSTEMIC-LUPUS-ERYTHEMATOSUS; IDIOTYPIC NETWORK MODEL; STATIONARY STATES; DNA; DISEASE; MICE; AUTOANTIBODIES; DYNAMICS; OSCILLATIONS; SUPPRESSION;
D O I
10.1016/j.jtbi.2012.09.017
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Autoimmune glomerulonephritis (GN) is a potentially life-threatening renal inflammation occurring in a significant percentage of systemic lupus erythematosus (SLE) patients. It has been suggested that GN develops and persists due to a positive feedback loop, in which inflammation is promoted by the deposition in the kidney of immune complexes (IC) containing double-stranded DNA (dsDNA) and autoantibodies specific to it, leading to cellular death, additional release to circulation of dsDNA, continuous activation of dsDNA-specific autoreactive B cells and further formation of IC. We have recently presented a generic model exploring the dynamics of IC-mediated autoimmune inflammatory diseases, applicable also to GN. Here we extend this model by incorporating into it a specific B cell response targeting anti-dsDNA antibodies a phenomenon whose occurrence in SLE patients is well-supported empirically. We show that this model retains the main results found for the original model studied, particularly with regard to the sensitivity of the steady state properties to changes in parameter values, while capturing some disease-specific observations found in GN patients which are unaccountable using our previous model. In particular, the extended model explains the findings that this inflammation can be ameliorated by treatment without lowering the level of anti-dsDNA antibodies. Moreover, it can account for the inverse oscillations of anti-dsDNA and anti-anti-dsDNA antibodies, previously reported in lupus patients. Finally, it can be used to suggest a possible explanation to the so-called regulatory role of TLR9, found in murine models of lupus; i.e., the fact that the knockdown of this DNA-sensing receptor leads, as expected, to a decrease in the level of anti-dsDNA antibodies, but at the same time results in a counter-intuitive amplification of the autoreactive immune response and an exacerbated inflammation. Several predictions can be derived from the analysis of the presented model, allowing its experimental verification. (C) 2012 Published by Elsevier Ltd.
引用
收藏
页码:8 / 22
页数:15
相关论文
共 50 条
  • [21] Clinical significance of ELISA positive and immunofluorescence negative anti-dsDNA antibody
    Kim, Kyeong Hee
    Han, Jin Yeong
    Kim, Jeong Man
    Lee, Sung Won
    Chung, Won Tae
    CLINICA CHIMICA ACTA, 2007, 380 (1-2) : 182 - 185
  • [22] Evaluation of a new automated enzyme fluoroimmunoassay using recombinant plasmid dsDNA for the detection of anti-dsDNA antibodies in SLE
    Villalta, D
    Bizzaro, N
    Corazza, D
    Tozzoli, R
    Tonutti, E
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2002, 16 (05) : 227 - 232
  • [23] Anti-C1q, anti-chromatin/nucleosome, and anti-dsDNA antibodies in juvenile systemic lupus erythematosus patients
    de Jesus, Adriana Almeida
    Arruda Campos, Lucia Maria
    Liphaus, Bernadete Lourdes
    Carneiro-Sampaio, Magda
    Pitangueira Mangueira, Cristovao Luis
    Rosseto, Eliane Aparecida
    Almeida da Silva, Clovis Artur
    Scheinberg, Morton
    REVISTA BRASILEIRA DE REUMATOLOGIA, 2012, 52 (06) : 971 - 981
  • [24] Exposure of chromatin and not high affinity for dsDNA determines the nephritogenic impact of anti-dsDNA antibodies in (NZBNZW)F1 mice
    Mjelle, Janne Erikke
    Kalaaji, Manar
    Rekvig, Ole Petter
    AUTOIMMUNITY, 2009, 42 (02) : 104 - 111
  • [25] Enhancement of hydroxyl radical DNA cleavage by serum anti-dsDNA antibodies in SLE
    Watanabe, N
    Kubota, T
    Miyasaka, N
    Kanai, Y
    LUPUS, 1998, 7 (02) : 108 - 112
  • [26] A bispecific dsDNA x monoclonal antibody construct for clearance of anti-dsDNA IgG in systemic lupus erythematosus
    Lindorfer, MA
    Schuman, TA
    Craig, ML
    Martin, EN
    Taylor, RP
    JOURNAL OF IMMUNOLOGICAL METHODS, 2001, 248 (1-2) : 125 - 138
  • [27] What is the clinical significance of anti-Sm antibodies in systemic lupus erythematosus? A comparison with anti-dsDNA antibodies and C3
    Flechsig, A.
    Rose, T.
    Barkhudarova, F.
    Strauss, R.
    Klotsche, J.
    Daehnrich, C.
    Schlumberger, W.
    Enghard, P.
    Burmester, G-R
    Hiepe, F.
    Biesen, R.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2017, 35 (04) : 598 - 606
  • [28] Linking complement and anti-dsDNA antibodies in the pathogenesis of systemic lupus erythematosus
    Brendan M. Giles
    Susan A. Boackle
    Immunologic Research, 2013, 55 : 10 - 21
  • [29] Anti-dsDNA antibody testing in the clinic: Farr or ELISA?
    Mahler, Michael
    Fritzler, Marvin J.
    NATURE CLINICAL PRACTICE RHEUMATOLOGY, 2007, 3 (02): : 72 - 73
  • [30] Linking complement and anti-dsDNA antibodies in the pathogenesis of systemic lupus erythematosus
    Giles, Brendan M.
    Boackle, Susan A.
    IMMUNOLOGIC RESEARCH, 2013, 55 (1-3) : 10 - 21